Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy

BACKGROUND: Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment for several mature B-cell malignancies. Reactivation of hepatitis B virus (HBV) is a well-described complication in patients with chronic HBV infection or prior HBV exposure undergoing cytotoxic or immunos...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Lok-Ka, Chan, Thomas Sau Yan, Hwang, Yu-Yan, Mak, Lung-Yi, Seto, Wai-Kay, Kwong, Yok-Lam, Yuen, Man-Fung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394758/
https://www.ncbi.nlm.nih.gov/pubmed/37528444
http://dx.doi.org/10.1186/s12985-023-02140-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394758/
https://www.ncbi.nlm.nih.gov/pubmed/37528444
http://dx.doi.org/10.1186/s12985-023-02140-w

Ejemplares similares